Pharmacyclics, Inc. (NASDAQ:PCYC)

Skyrocketed based on expectations; no tangible results & more lofty expectations based on today's valuation compared to most other biotechs

Strictly going off the genius Baker Brothers buying the stock. The fundamentals of this company look like any other infant-stage biotech... awful.

There are currently 200 PCYC shares in my "fund" with break-even of around 14.99 USD. http://caps.fool.com/Blogs/fund-trades/678775.

investors will get impatient waiting for the drug to get through future trials IMHO

ok ok so here is the truth.
This company is losing money and will continue to loose money untill it's products gain FDA approval. There are 2 problems with this. The main problem is they may never gain FDA approval. The scaond problem is they will not gain approval any time soon.
This company has 68.7 Million shares outstanding.
2011 Q2 loss of .13 per share
2011 Q3 loss of .15 per share
2011 Q4 loss of .18 per share
2012 Q1 projected loss .21 per share
In essence they lose money!!!
They lose more money each quarter!!!
They lose more money per share than last quarter!!!
This stock will eventually fall, and when it does it will fall fast and hard.

Insider bought 6m worth of shares at 8.85 each. Cash rich. This is a tracker.

All pharm companies have been doing great in the past few weeks. With new drug technology, it is best pick for short term and long term gains.

its undervalue with big insider buy , my target 12 $

heavy accumulation

Well....back in 2000 hit 80.00....undervalued...4star watch...i'm in!!!

This is a great stock... To short. Pump and dump; today is 01/8/10 and they've been enjoying a 105% rally for the past month

I copy UL what else can I say, and he's usually right - selfcentric as he is :-)

Ultralong

Well, looks like Papa's got a brand new bag...of crap stocks and lookie lookie, Pharmacyclics is high up on that list!

Pharmacyclics...what can I say? Where else can you call a 16 patient first phase trial a resounding success and shoot your market capitalization up 60M in a matter of days? Have you produced a profit for your shareholders? No. Are you burning through your 33M in remaining cash? Yes. Can I ask yes or no questions all day? Sure.

This is going to be a story we're talking about in 9-18 months of a company who's stock plummetts 60-70% in one day because their "only" drug crapped out in trials.

UltraLong

Pharmacyclic's market cap has now increased six-fold from March despite heavy dilution and a prominent absence of positive catalysts. The albatross Xcytrin remained quiescent and will likely resume its downward spiral in 2010 with crappy data in primary brain tumors. Meanwhile the next wave of anti-tumor chaff cycles through early phase trials. 2009 has turned out to be a banner year for failed biotechs seeking redemption, and a new generation of bagholders has been born.

This swine flu mover has turned the corner and lost its momentum. It's just not worth $2.

... the insider buying in PHARMACYCLICS, INC is not real insider, but a benefial owner, which happens to be a company called Robert W Duggan, check http://www.dugganassociates.com

Now...the problem is, most of these money management companies don't beat the markets, specially the ones focusing in small stocks. I checked what they said in the page and they "predict future prices"... well, and I say, they can do that because nobody else can.
Robbert W Duggan sells bad funds and invest in stocks in a way that will yield random results.

I checked their fee structure...a very tipical money scam, 20% of the profits!!! Likely they will take high risks to have high profits, if all the money is lost they won't have to pay 20% of what you lost.... so, one more case of unbalanced probabilities relating to rewards.

I regret having picked this company, I think it's time to read more about the company, then lick my wounds and close it.

After the Dendreon panel recommendation, Pharmacyclics made a filing with the FDA that among other things seeks a review of Xcytrin by an outside panel of experts. This coupled with lung cancer advocacy group involvement increases the chances of a favorable outcome regarding FDA approval.

NDA filed for Xcytrin and with Fast Track status should have a response from the FDA by June 2007. Insider buying activity is very bullish indicating they think they'll get approval. Company owns 100% of all North America revenue with expectations of capturing 50% of the 150K cases per year for Brain Mets in the US. Comparing to other companies rev/patient might bring $14K. Do that math and this could get very interesting as the year goes by.